期刊
CANCER JOURNAL
卷 18, 期 2, 页码 142-147出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/PPO.0b013e31824d448c
关键词
Melanoma; PI3K; AKT; PTEN; targeted therapy
类别
资金
- American Society of Clinical Oncology
- Melanoma Research Alliance
- GlaxoSmithKline
- Genentech
- AstraZeneca
- Merck
- Myriad
The PI3K (phosphatidylinositol 3-kinase)-AKT pathway is one of the most important signaling networks in cancer. There is growing evidence that activation of this pathway plays a significant role in melanoma, frequently in the setting of concurrent activation of RAS-RAF-MEK-ERK signaling. This evidence includes the identification of genetic and epigenetic events that activate this pathway in melanoma cell lines and clinical specimens. In addition, functional experiments have demonstrated important roles for the PI3K-AKT pathway in both melanoma initiation and therapeutic resistance. The availability of many inhibitors against the PI3K-AKT pathway is rapidly leading to the development of trials that will ultimately determine its clinical significance in this disease. The rational development of such therapies will be facilitated by strategies that utilize the growing understanding of the complexity of the regulation and roles of this pathway.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据